L-carnitine: Searching for New Therapeutic Strategy for Sepsis Management

Sahebnasagh, Adeleh; Avan, Razieh; Monajati, Mahila; Hashemi, Javad; Habtemariam, Solomon; Negintaji, Sina; Saghafi, Fatemeh

doi:10.2174/0929867328666211117092345

Cited by 3 publications

(2 citation statements)

References 175 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It should also be noted that L-carnitine inhibits lipid peroxidation, reduces oxidative stress, such as ROS, improves mitochondrial function, and thus plays a pivotal role in reducing inflammation [ 29 ]. Additionally, L-carnitine is thought to be a booster of the immune system (such as increasing the function of macrophages), which is involved in reducing infection and inflammation [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

Effects of L-carnitine supplementation in patients with mild-to-moderate COVID-19 disease: a pilot study

et al. 2022

View full text Add to dashboard Cite

Background The present single-center clinical trial was designed to evaluate the potential benefits of L-carnitine supplementation in patients with COVID-19 disease. Methods and patients The study was conducted on 75 patients with mild-to-moderate COVID-19 hospitalized in Shahid Beheshti Hospital-Hamadan, IRAN. The participants were randomly divided into intervention ( n = 32) and control groups ( n = 43). The control group received their standard hospital treatment only. In addition to standard medications, the intervention group received 3000 mg oral L-carnitine daily in three divided doses for five days. The blood samples were collected and para-clinical parameters were measured at the beginning and end of the treatment. Clinical outcomes were also recorded, and data were analyzed using χ 2 and t -tests. Results Higher means of O2 saturation were observed in the intervention rather than in the control group. Mean erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were significantly lower in the intervention group. Furthermore, mean alkaline phosphatase (ALP) activity and lactate dehydrogenase (LDH) were lower in the intervention group. Also, lower mean serum creatine phosphokinase (CPK) was observed in the intervention group. No significant differences were observed in terms of clinical symptoms; however, six patients (14%) in the control group died due to the complications of COVID-19, while all patients in the intervention group survived. Conclusion Taken together, L-carnitine can be considered as a drug supplement in patients with COVID-19. Supplementary Information The online version contains supplementary material available at 10.1007/s43440-022-00402-y.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of L-carnitine supplementation in patients with mild-to-moderate COVID-19 disease: a pilot study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…According to previous studies, l -carnitine supplementation greater than 2 gr/day might have a greater beneficial effect. Finally, we decided to select 3 gr as the appropriate intervention with low adverse effects [ 19 , 20 ]. The l -carnitine capsule and identical placebo will be labeled by the clinical pharmacist with a unique code that will be produced by the www.sealedenvelope.com website and prescribed to the patients using a double-blind procedure.…”

Section: Study Design and Settingmentioning

confidence: 99%

The effect of l-carnitine supplementation on mortality and clinical outcomes in ventilator-dependent critically ill patients with obesity and COVID-19: Protocol for a randomized double-blind placebo-controlled trial

Arabi¹,

Hadi²,

Gholambareshi³

et al. 2023

Contemporary Clinical Trials Communications

View full text Add to dashboard Cite

Research on the embryotoxic effect and carcinogenicity of the drug “BTF plus” – a means for normalizing metabolic processes in animals and poul-try

Sachuk,

Gutyj,

Radzyhovskyi

et al. 2023

Ukr. Jour. of Vet. and Agr. Sci.

View full text Add to dashboard Cite

Laboratory studies were conducted to determine the embryotoxic effect and carcinogenicity of the veterinary drug “BTF plus” on white rats and white mice. The drug “BTF plus” is a complex vitamin-mineral drug based on butophosphane, L-carnitine, and cyanocobalamin, which is used to normalize and correct metabolic processes in animals and poultry. The drug is used for various types of animals and poultry as a stimulating, tonic and general strengthening agent for obstetric pathologies (complicated childbirth, postpartum complications, paresis, eclampsia, sexual cycle disorders); metabolic disorders caused by irrational feeding, malnutrition, asthenic syndrome, etc.; anemia with helminthiasis; secondary anemias, as an additional means in the treatment of magnesium and calcium deficiency; to increase muscle activity, with significant loads, overstrain and exhaustion in animals; to increase the body's resistance to various pathogens; to stimulate growth, development and live weight gain in young animals and poultry; as an additional means in the treatment of diseases caused by various factors (infectious and non-infectious origin). The drug “BTF plus”, under the conditions of subcutaneous administration to pregnant female rats in doses (based on the absolute weight of the drug) of 200.0 and 2000.0 mg/kg of body weight, does not cause death and pathological changes in embryos do not have an embryotoxic and teratogenic effect since indicators of total, preimplantation, and postimplantation embryonic lethality in rats of the experimental groups had no significant differences compared to indicators in control and also did not show changes in the weight of the placenta, fetuses, and their cranio-caudal size. The drug “BTF plus”, under conditions of 5-day subcutaneous administration to white mice in doses (based on the absolute weight of the drug) of 200.0 and 2000.0 mg/kg of body weight, does not show a carcinogenic effect (during microscopic studies, the proportion of polychromatophilic erythrocytes was not probable deviations between themselves and was 0.117-0.133%, which is within the normal range of up to 0.2 %). Further studies will be the next stage of pre-registration tests aimed at studying the ecotoxicity of “BTF plus”, which is a mandatory material of the “Safety and residue studies” section of the dossier for this drug.

show abstract

L-carnitine: Searching for New Therapeutic Strategy for Sepsis Management

Cited by 3 publications

References 175 publications

Effects of L-carnitine supplementation in patients with mild-to-moderate COVID-19 disease: a pilot study

Effects of L-carnitine supplementation in patients with mild-to-moderate COVID-19 disease: a pilot study

The effect of l-carnitine supplementation on mortality and clinical outcomes in ventilator-dependent critically ill patients with obesity and COVID-19: Protocol for a randomized double-blind placebo-controlled trial

Research on the embryotoxic effect and carcinogenicity of the drug “BTF plus” – a means for normalizing metabolic processes in animals and poul-try

Contact Info

Product

Resources

About